ENYO Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline
- 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect
- Company plans to advance vonafexor to Phase 3 in Alport Syndrome
Lyon, France – January 8, 2026 – ENYO Pharma (“ENYO”),
63rd ERA congress, the Annual Nephrology Congress in Europe
ENYO Pharma will participate in the 63rd ERA congress scheduled for June 3-6, 2026, in Glasgow, UK. The event will highlight advancements and discussions in nephrology, contributing to the ongoing dialogue in the field. More information is available at the ERA website.
J.P. Morgan week in San Francisco
11-15 January, 2025
San Francisco, CA, USA
ENYO Pharma will be in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ASN – the American Society of Nephrology 2025
5-9 November 2025
Houston, Texas
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN.
The 2025 International Workshop on Alport Syndrome
5-7 September 2025
Beijing, China
ENYO Pharma will attend The 2025 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.
ENYO Pharma will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
Latest Press Release 